Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: new discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication-Reference-Cited by-同舟云学术

Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: new discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication

Published:2012-10-03 Issue:1 Volume:10 Page:
ISSN:1741-7015
Container-title:BMC Medicine
language:en
Short-container-title:BMC Med

Author:

Arts Eric J

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1186/1741-7015-10-114.pdf

Reference18 articles.

1. Brun-Vezinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, Jeffries D, Kaye S, Krzyanowski C, Nunn A, Schuurman R, Seigneurin JM, Tamalet C, Tedder R, Weber J, Weverling GJ: HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Lancet. 1997, 350: 983-990. 10.1016/S0140-6736(97)03380-1.

2. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996, 335: 1081-1090. 10.1056/NEJM199610103351501.

3. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La MA, Leonard JM, Ho D: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995, 333: 1534-1539.

4. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, Aguado AG, de Lomas JG, Delgado R, Borleffs JCC, Hsu A, Valdes JM, Boucher CAB, Cooper DA: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995, 333: 1528-1533. 10.1056/NEJM199512073332303.

5. Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N, Cameron J, Nicholson W: Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS. 1995, 9: 351-357.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs;Viruses;2021-01-29

2. Strong Selection Significantly Increases Epistatic Interactions in the Long-Term Evolution of a Protein;PLOS Genetics;2016-03-30

3. Exposure to MIV-150 from a High-Dose Intravaginal Ring Results in Limited Emergence of Drug Resistance Mutations in SHIV-RT Infected Rhesus Macaques;PLoS ONE;2014-02-27

4. HIV-1 drug resistance: where do polymorphisms fit in?;Future Microbiology;2013-03